Swedish Orphan Biovitrum
Clinical trials sponsored by Swedish Orphan Biovitrum, explained in plain language.
A biopharmaceutical company focused on rare diseases, now part of Sobi.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for myelofibrosis patients with dangerous low platelet counts Results expected Oct 2026 (estimated)
- Weekly shot may shield joints in hemophilia a patients Results expected Nov 2026 (estimated)
- New hope for rare inflammatory disease: pacritinib trial begins Results expected Dec 2026 (estimated)
- Real-World data may unlock Pacritinib's true potential in myelofibrosis Results expected Jan 2027 (estimated)
- New clotting factor offers continued bleeding control for hemophilia a patients Results expected Mar 2027 (estimated)
-
Can a targeted therapy tame rare kidney diseases in daily practice?
Disease control Recruiting nowThis study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New study tracks Real-World impact of hemophilia drug on joint health
Disease control Recruiting nowThis study follows 250 people with hemophilia A who are taking efanesoctocog alfa to prevent bleeding. Researchers want to see how well it protects joints from bleeds over time in everyday life. Participants will be observed for several years to track bleeding rates and treatment…
Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New clotting factor offers continued bleeding control for hemophilia a patients
Disease control Recruiting nowThis study gives people with moderate or severe hemophilia A who finished a previous trial continued access to the drug efanesoctocog alfa. The drug is a lab-made clotting factor that helps prevent bleeding episodes. Researchers will monitor safety and how well it controls bleedi…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Real-World data may unlock Pacritinib's true potential in myelofibrosis
Knowledge-focused Recruiting nowThis study looks back at medical records of adults with myelofibrosis who took pacritinib for at least a month. Researchers will track changes in spleen size, blood counts, symptoms, and survival to see how the drug performs in everyday practice. The goal is to understand real-wo…
Sponsor: Swedish Orphan Biovitrum • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC